Publications by authors named "Y Y Soon"
Research productivity of RANZCR radiation oncology trainees from 2014 to 2023.
J Med Imaging Radiat Oncol
October 2024
Introduction: The aim of this study was to describe the research productivity among RANZCR Radiation Oncology (RO) trainees.
Methods: Publicly available data on RO fellows, who were awarded the RANZCR fellowship between July 2014 and June 2023, was extracted from the RANZCR Annual Reports. Fellows who had qualified overseas and did not undertake full RANZCR training were excluded.
Importance: Observed treatment effects on overall survival (OS) differed substantially in the first 2 randomized clinical trials of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer.
Objective: To investigate factors associated with the observed difference in treatment effects on OS, including differences in the risk of crossover from randomized treatment after disease progression.
Design, Setting, And Participants: This comparative effectiveness study used individual participant data from 2 randomized clinical trials, TheraP (A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer [ANZUP Protocol 1603]) (n = 200), recruited from February 2018 to September 2019 in Australia, and published data from VISION (An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer) (n = 831), recruited from June 2018 to October 2019 in North America and Europe.
Article Synopsis
- - This research examines why positive treatment effects seen in the first interim analysis of clinical trials may decline in later analyses, focusing on issues like overestimation bias, non-proportional hazards, and varied recruitment.
- - The study analyzed 71 oncology randomized clinical trials, showing that hazard ratios often overestimate treatment effects, especially when fewer events have occurred by the interim analysis.
- - The findings highlight the need to apply adjusted hazard ratios to reduce overestimation bias and stress the importance of considering various factors when reporting on positive interim analysis results.
Article Synopsis
- The study examined whether comprehensive geriatric assessment (CGA)-guided care enhances health-related quality of life (HRQL) in older cancer patients compared to standard care.
- Meta-analyses showed a potential moderate improvement in HRQL scores at 3 months, though results were not definitive and depended on the size and type of trials.
- Overall, findings suggested that larger RCTs and those requiring CGA before cancer treatment were more likely to show better HRQL outcomes.
Article Synopsis
- Patients with advanced non-small-cell lung cancer (NSCLC) and brain metastases are often treated with osimertinib, but the effectiveness of adding stereotactic radiosurgery (SRS) is uncertain.
- This study proposes a meta-analysis of existing trials to determine if SRS combined with osimertinib improves control of brain metastases compared to osimertinib alone.
- The research will evaluate various outcomes, including intracranial progression-free survival and overall survival, and will be shared with the medical community and patients through publications and presentations.*